Johnson & Johnson (JNJ) Stock Price Quote, News & Filings

Summary

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Website

www.jnj.com

Location

New Brunswick, NJ, US

Phone732 524 0400

Employees141,700

CEOJoaquin Duato

Sector

Health Care

Industry

Pharmaceuticals

Ask AI

Company overview

Business model, segments, and competition.

Peer comparison

Metrics vs closest competitors.

Guidance & outlook

Forward guidance and assumptions.

Bull vs bear case

Upside drivers and key risks.

Valuation snapshot

Multiples vs history and peers.

Competitive moat

Defensibility and market position.

Management track record

Leadership and capital allocation history.

How it makes money

A short diagram of the business model.

Latest Documents

Mentions in Filings

… ation Agreement in January 2023, which was amended in June 2026 (see Note 6). The Company also leased certain laboratory and office space from Lilly under a lease agreement that expired in August 2026 (see Note 5). Johnson & Johnson Innovation Johnson & Johnson Innovation – JJDC, Inc. (“Johnson & Johnson Innovation”) held more than 5% of the Company’s outstanding capital stock as of December 31, 2025 and September 30, 2026. In addition, an affi …
TRex Bio, Inc.Johnson & Johnson·10-Q - Quarterly report Q3·Q3 26·04:30PM
… inical trial for PH-ILD, and Pulmovant’s Mosliciguat in a Phase 3 clinical trial for PH-ILD. In SAPH, we are aware of products marketed for the treatment of PAH which are frequently used off-label in SAPH patients, including drugs manufactured by Bayer, Eli Lilly, Gilead, Johnson & Johnson, Liquidia, Pfizer, and United Therapeutics. We believe that LAM-001 for the treatment of SAPH has the potential to be used in combination with these therapies.
IRulya Therapeutics Inc.Johnson & Johnson·10-Q - Quarterly report Q3·Q3 26·04:01PM
… rom 2013 to 2014, he served as Chief Financial Officer of 1WorldSync, a global cloud-based product data management company. Previously, Mr. Lo held progressively senior finance and technology leadership positions at Johnson & Johnson from 2003 to 2013, including Finance and IT Director for Vision Care Asia Pacific, as well as finance leadership positions at Siebel Systems from 2000 to 2003 and Boston Scientific from 1996 to 2000. Mr. Lo began his …
SS Innovations International, Inc.Johnson & Johnson·8-K - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers·Q4 26·08:56AM
… Systems; and Chief Financial Officer of 1WorldSync, a global cloud-based product data management company. At the start of his career, Mr. Lo held progressively senior finance and technology leadership positions at Johnson & Johnson, finance leadership positions at Siebel Systems and Boston Scientific, and a senior auditor role at PricewaterhouseCoopers. Mr. Lo is a licensed Certified Public Accountant (CPA). He earned a Master of Business Admin …
SS Innovations International, Inc.Johnson & Johnson·EX-99.1 - 8-K - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers·Q4 26·08:56AM
… final regulatory alignment. Corporate Update In a separate press release issued today, we announced the appointment of Vanina Popova, MD, as Chief Development Officer, to lead the clinical development of GH001 into our pivotal programs. Dr. Popova was previously at Johnson & Johnson, where she worked on the clinical development of Spravato® (esketamine) and was the lead author of the publication of TRANSFORM-2, its pivotal Phase 3 trial in TRD.
GH Research PLCJohnson & Johnson·EX-99.2 - 6-K - EXHIBIT 99.2·Q3 26·08:22AM
… n=95; primary endpoint Day 28; remission at Day 8: 10.1%. Spravato® 56 mg: remission 13.1% (Day 2), 7.1% (Day 8) and 14.6% (Day 28). 2026E = nine months actual ($1,676m) plus Q4 at the Q3 2026 level ($624m); GH estimate, not Johnson & Johnson guidance. Sources: 1. Johnson & Johnson quarterly and annual results; 2. Cubała WJ et al., JAMA Psychiatry 2026;83(6):561-569; Janik A et al., JAMA Psychiatry 2025;82(9):877-887. 2026© GH Research PLC 9 ---
GH Research PLCJohnson & Johnson·EX-99.4 - 6-K - EXHIBIT 99.4·Q3 26·08:22AM

Key Stats

Trading

Px/Chg 1D$256.03 / -1.02%

Avg Volume8.11M

Beta-0.11

Mkt Cap617.01B

FD Mkt Cap641.50B

Float

Shrs Out/Float2.41B / 2.41B

Short Float0.01%

Days to Cover2.48

Stock Repurchased$4.03B

Current Valuation

EV650.31B

EV/EBITDA19.42

EV/Sales6.75

P/B7.60

P/S6.40

FCF Yield0.24%

ROE6.45%

ROA2.61%

Current Ratio1.03

Dividend

Cash$1.34

Yield2.28%

Yield (TTM)2.28%

Estimates

P/E29.33

Est P/E0.00

Est EPS2.68

Est PEG0.00

Valuation

Metric	5Yr Avg	Apr '23	Apr '24	Apr '25	Apr '26	Oct '26
PRICE-BASED RATIOS
Price / Earnings	75.46	121.03	10.42	27.00	107.36	111.49
Price / Sales	14.66	17.97	4.30	4.28	22.36	24.38
Price / Book Value	6.10	5.55	5.33	5.31	6.74	7.60
Price / Free Cash Flow	117.11	24.79	20.07	19.14	100.38	421.16
ENTERPRISE VALUE METRICS
Enterprise Value	489,324.6	452,769.3	373,791.8	392,280.6	577,476.2	650,305.3
Enterprise Value / Sales	15.42	19.10	4.39	4.42	23.51	25.69
Enterprise Value / EBITDA	55.29	73.62	16.03	15.83	80.31	90.65
Enterprise Value / EBIT	70.33	103.42	23.61	22.49	111.48	90.65

Financials

Full Financials

Millions USD	5Yr CAGR (%)	Jan '22	Jan '23	Dec '23	Dec '24	Dec '25
INCOME STATEMENT
Revenue	4.6%	78,740.0	79,990.0	85,159.0	88,821.0	94,193.0
Gross Income	5.5%	55,338.0	55,394.0	58,606.0	61,350.0	68,558.0
EBITDA	11.3%	26,751.0	26,605.0	23,320.0	24,781.0	41,055.0
EBIT	14.7%	19,361.0	19,635.0	15,834.0	17,442.0	33,552.0
Net Income	6.4%	20,878.0	17,941.0	35,153.0	14,066.0	26,804.0
EPS (Diluted)	9%	7.81	6.73	13.72	5.79	11.03
BALANCE SHEET
Cash & ST Inv	-10.7%	31,608.0	22,281.0	22,927.0	24,522.0	20,102.0
Total Assets	2.3%	182,018.0	187,378.0	167,558.0	180,104.0	199,210.0
Total Liabilities	2.2%	107,995.0	110,574.0	98,784.0	108,614.0	117,666.0
Total Shareholder Equity	2.4%	74,023.0	76,804.0	68,774.0	71,490.0	81,544.0
CASH FLOW
Net Operating Cash Flow	1.2%	23,410.0	21,194.0	22,791.0	24,266.0	24,530.0
Cap Ex	7.3%	-3,652.0	-4,009.0	-4,543.0	-4,424.0	-4,832.0
Free Cash Flow	-7.6%	19,758.0	17,185.0	18,248.0	19,842.0	19,698.0

Enterprise Value Bridge

Millions USD		13 Nov '26
Price (As of 13 Nov '26)		286.11
Basic Shares		2,409.90
Market Cap		689,496.0
Diluted Shares		2,448.60
Fully Diluted Shares Outstanding		2,448.60
Fully Diluted Market Cap		700,568.9
+Consolidated Debt		44,651.0
−In-the-Money Convertible Debt		—
+Capital Leases		-
+Operating Leases		—
−Cash & Equivalents		-16,910.0
−Short-term Investments		-318.0
+Total Preferred		-
−In-the-Money Convertible Preferred		—
−Investments in Unconsolidated Subs		—
+Non-Controlling Interest		-
+Pension Liabilities		—
Enterprise Value		717,237.0

Segment data

Revenue

by Products and services

Innovative Medicine64%
Medtech36%